Guangxi Wuzhou Zhongheng Group Co Ltd
SSE:600252
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (4.7), the stock would be worth ¥1.52 (38% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 7.6 | ¥2.46 |
0%
|
| 3-Year Average | 4.7 | ¥1.52 |
-38%
|
| 5-Year Average | 4.1 | ¥1.34 |
-46%
|
| Industry Average | 7.6 | ¥2.44 |
-1%
|
| Country Average | 13.6 | ¥4.38 |
+78%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Guangxi Wuzhou Zhongheng Group Co Ltd
SSE:600252
|
7.8B CNY | 7.6 | -21.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 17.4 | 44.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 8.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 6.3 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 6.2 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 7.4 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 5.8 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 160.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 5.3 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 4.2 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 4.3 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8 |
| Median | 13.6 |
| 70th Percentile | 23.3 |
| Max | 17 898 541.1 |
Other Multiples
Guangxi Wuzhou Zhongheng Group Co Ltd
Glance View
Guangxi Wuzhou Zhongheng Group Co Ltd is an intriguing player nestled in China's vibrant industrial landscape. The company, with its roots firmly planted in the southeastern province of Guangxi, has carved a niche for itself in the pharmaceutical and health products sector. Since its establishment, Zhongheng Group has methodically expanded its operations, establishing a robust portfolio that includes everything from the cultivation and processing of Chinese medicinal herbs to the development and manufacturing of pharmaceutical products. This vertical integration ensures quality control from start to finish and allows the company to create an array of products, catering to a diverse market that values traditional Chinese medicine as much as modern health solutions. Zhongheng Group's revenue model hinges on its ability to efficiently blend traditional expertise with modern pharmaceutical practices, capitalizing on the increasing demand for health and wellness products. Through its comprehensive supply chain, the company can produce a competitive range of cost-effective pharmaceuticals and health supplements, positioning itself for profitability in a growing market. Additionally, the company's strategic emphasis on research and development facilitates innovation, allowing for the introduction of new products that meet evolving consumer needs. By maintaining a dynamic array of offerings and leveraging its integrated operations, Guangxi Wuzhou Zhongheng Group Co Ltd continues to navigate the competitive landscape of the pharmaceutical industry, ensuring its place as a key player in China's economic tapestry.